IGF-1 DES

The Canadian journal of urology · 2013

Researchers reviewed studies on the relationship between vitamin D and benign prostatic hyperplasia (BPH), a common condition affecting older men. They observed that higher vitamin D levels may be linked to a reduced prevalence of BPH and a decrease in prostate size.

• Researchers found that vitamin D may inhibit certain pathways involved in prostate cell growth, potentially reducing BPH symptoms.
• The review indicated that increased vitamin D intake is associated with a lower prevalence of BPH among men.
• No negative side effects were reported from higher vitamin D intake in the studies reviewed.

Oncogene · 2008

Researchers studied the effects of a specific form of insulin-like growth factor-1 (IGF-1) on prostate health in mice. They found that while increased IGF-1 led to abnormal growth in prostate cells, it also hindered the progression to cancer. Additionally, the study indicated that a lack of IGF-1 action may be necessary for the development of advanced cancer and metastasis.

• Increased IGF-1 caused abnormal growth in prostate cells but did not lead to cancer within a year.
• Crossbreeding with a prostate cancer model delayed tumor progression and spread in younger mice.
• Older mice showed widespread metastasis, but the specific IGF-1 variant was not found in advanced tumors.

Journal of neurophysiology · 2005

Researchers studied the effects of a specific form of insulin-like growth factor-1 (des-IGF-1) on brain function in young rats. They found that des-IGF-1 significantly increased synaptic transmission in a brain region important for learning and memory, suggesting it may play a role in cognitive improvements.

• Researchers observed a 40% increase in synaptic transmission in the hippocampus after applying des-IGF-1.
• The enhancement in synaptic activity was linked to a specific type of receptor (AMPA) and involved certain cellular signaling pathways.
• These findings may help explain how long-term increases in IGF-1 levels can benefit cognitive function in older animals.

International journal of experimental diabesity research · 2003

Researchers observed that an insulin-like growth factor (IGF)-1 analog could prevent early biochemical changes in the retinas of diabetic rats, which are associated with the progression of diabetic eye disease. Despite ongoing high blood sugar levels, the treatment reduced abnormal protein accumulations in the retina.

• Type 1 IGF receptor levels increased significantly in the retinas of diabetic rats compared to healthy controls.
• Phospho-Akt levels, which are linked to cell survival, were also found to be much higher in diabetic rat retinas.
• Treatment with the IGF-1 analog reduced these abnormal protein levels in the retinas of diabetic rats.

Molecular and cellular biochemistry · 2002

Researchers studied the effects of a substance called des IGF-I on muscle activation in mice. They found that while des IGF-I did not change insulin or IGF-I levels, it significantly reduced blood sugar levels and activated specific pathways in skeletal and cardiac muscles differently.

• Des IGF-I reduced plasma glucose levels by about 50%.
• It increased the activation of a protein called Akt-1 in both skeletal and cardiac muscles.
• Skeletal muscle showed increased activation of p70 S6K, while cardiac muscle did not.

Endocrinology · 2001

Researchers found that a protein called IGFBP-3 can inhibit the activation of a specific receptor involved in cell signaling, known as the type 1 IGF receptor, without directly binding to it. This study highlights a unique regulatory mechanism that IGFBP-3 employs, which does not affect other related receptors, such as the insulin receptor.

• IGFBP-3 significantly reduces the activation of the type 1 IGF receptor in breast cancer cells.
• The inhibitory effect of IGFBP-3 is specific to the IGF receptor and does not impact the insulin receptor.
• IGFBP-3's ability to modulate IGF signaling occurs independently of its binding to IGF.

Neuroendocrinology · 2000

Researchers studied how insulin-like growth factor-1 (IGF-1) crosses the blood-brain barrier (BBB) and its behavior in the brain and spinal cord. They found that IGF-1 can enter the brain quickly and remains intact for a short period, suggesting a specific transport system at the BBB that regulates its availability to the central nervous system.

• Researchers observed that IGF-1 has a half-life of 4.5 minutes in blood and can enter the brain and spinal cord effectively after intravenous injection.
• The influx rate of IGF-1 into the brain was measured at 0.4 microl/g x min, indicating a significant transport mechanism.
• The study found that the presence of nonradiolabeled IGF-1 enhances the influx of IGF-1 into the brain when injected, but not during direct brain perfusion.

Hormone research · 1998

Researchers found that insulin-like growth factors (IGFs) are crucial for brain growth and development, particularly in the olfactory bulb. The study observed that IGF-1 can help protect brain cells from damage after injury, while specific binding proteins play an important role in delivering IGFs to their targets. Overall, the IGF system shows promise for supporting brain health and recovery.

• IGF-1 and its binding proteins are highly active in the developing brain, especially in the olfactory bulb.
• IGF-1 helps protect neurons from cell death after injury, enhancing their survival.
• Binding proteins are essential for effectively transporting IGFs to their receptors, influencing brain cell responses.

Endocrinology · 1996

Researchers studied the effects of insulin-like growth factors on brain injury in rats. They found that IGF-1 reduced neuronal loss after a brain injury, while IGF-2 appeared to increase neuronal loss and counteracted the protective effects of IGF-1.

• IGF-1 significantly reduced neuronal loss in various brain regions after injury.
• IGF-2 was found to increase neuronal loss in certain areas of the brain.
• The presence of IGF binding proteins may influence the protective effects of IGF-1.

The Biochemical journal · 1989

Researchers studied how certain proteins, known as IGF-binding proteins, affect the actions of insulin-like growth factors IGF-1 and IGF-2. They found that these binding proteins can inhibit the growth-promoting effects of IGF-1 and IGF-2 but do not affect a variant called des-(1-3)-IGF-1.

• Researchers found that a binding protein from bovine kidney significantly reduced the ability of IGF-2 to stimulate cell growth and protein production.
• The study observed that des-(1-3)-IGF-1 was not influenced by the binding proteins, indicating it remains more active than IGF-1 and IGF-2.
• Researchers noted that the effectiveness of IGF-1 and IGF-2 is inversely related to their binding to these proteins, suggesting that less binding leads to greater biological activity.